Mankind Pharma Share PriceMankind Pharma

₹1750.7
8.15 (0.47%)
  • Advice
  • Hold
As on 26 September, 2023 | 23:51 BSE: 543904 NSE: MANKINDISIN: INE634S01028

Mankind Pharma Performance

Day Range

  • Low 1747.05
  • High 1776.55
1750.7

52 Week Range

  • Low 1242
  • High 1949
1750.7
  • Open Price1776.1
  • Previous Close1742.55
  • Volume84803

Start SIP in Mankind Pharma

Start SIP

Mankind Pharma Share Price

  • Over 1 Month -1.94%
  • Over 3 Month 2.81%

Mankind Pharma Key Statistics

P/E Ratio
PEG Ratio
Market Cap Cr 70,131
Price to Book Ratio 9.2
EPS 30.4
Dividend 0
Relative Strength Index 46.56
Money Flow Index 66.23
MACD Signal -11.26
Average True Range 45.07

Mankind Pharma Investment Rating

  • Master Rating:
  • Mankind Pharma Ltd has an operating revenue of Rs. 8,447.98 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 19% is great, ROE of 17% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 10% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 43 which is a POOR score indicating inconsistency in earnings, a RS Rating of 47 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 111 indicates it belongs to a poor industry group of Medical-Products and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Mankind Pharma Financials
IndicatorJun 2023Mar 2023Dec 2022Mar 2022
Oper Rev Qtr Cr 2,3001,8721,9361,645
Operating Expenses Qtr Cr 1,7611,4911,5631,336
Operating Profit Qtr Cr 539381373309
Depreciation Qtr Cr 69677136
Interest Qtr Cr 21911
Tax Qtr Cr 117747753
Net Profit Qtr Cr 409281249217
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 8,2907,420
Operating Expenses Annual Cr 6,4305,457
Operating Profit Annual in Cr 1,6971,800
Depreciation Cr 270121
Interest Annual Cr 2844
Tax Annual Cr 315462
Net Profit Annual Cr 1,2481,335
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 1,799812
Cash from Investing Activity Annual Cr -1,041-1,369
Cash from Financing Annual Activity Cr -710579
Net Cash Flow Annual Cr 4822
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 7,7846,069
Fixed Assets Annual Cr 3,6373,273
Total Non Current Assets Annual Cr 5,8545,156
Total Current Assets Annual Cr 3,5173,257
Total Assets Annual Cr 9,3718,413
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 194151
ROE Annual % 1622
ROCE Annual % 2030
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2327
IndicatorJun 2023Mar 2023Dec 2022Mar 2022
Oper Rev Qtr Cr 2,5792,0532,0911,726
Operating Expenses Qtr Cr 1,9241,6361,6541,441
Operating Profit Qtr Cr 655417437285
Depreciation Qtr Cr 87858547
Interest Qtr Cr 651313
Tax Qtr Cr 130848370
Net Profit Qtr Cr 494285284190
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 8,8787,978
Operating Expenses Annual Cr 6,8495,792
Operating Profit Annual in Cr 1,9011,989
Depreciation Cr 326167
Interest Annual Cr 4459
Tax Annual Cr 362522
Net Profit Annual Cr 1,2821,433
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 1,813920
Cash from Investing Activity Annual Cr -1,054-1,369
Cash from Financing Annual Activity Cr -740605
Net Cash Flow Annual Cr 19155
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 7,4356,155
Fixed Assets Annual Cr 4,7814,269
Total Non Current Assets Annual Cr 5,3884,741
Total Current Assets Annual Cr 4,3284,407
Total Assets Annual Cr 9,7159,148
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 190158
ROE Annual % 1723
ROCE Annual % 2231
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2328

Mankind Pharma Technicals

EMA & SMA

Current Price
₹1750.7
8.15 (0.47%)
  • Bullish Moving Average
  • ___
  • 2
  • Bearish Moving Average
  • ___
  • 9
  • 20 Day
  • ₹1765.97
  • 50 Day
  • ₹1751.09
  • 100 Day
  • 200 Day
  • 20 Day
  • ₹1764.76
  • 50 Day
  • ₹1805.62
  • 100 Day
  • 200 Day

Mankind Pharma Resistance and Support

PIVOT
₹1758.1
Resistance
First Resistance ₹1769.15
Second Resistance ₹1787.6
Third Resistance ₹1798.65
RSI 46.56
MFI 66.23
MACD Single Line -11.26
MACD -13.87
Support
First Resistance ₹1739.65
Second Resistance ₹1728.6
Third Resistance ₹1710.15

Mankind Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 88,665 5,095,578 57.47
Week 198,488 13,947,738 70.27
1 Month 280,543 19,851,233 70.76
6 Month 750,403 40,604,315 54.11

Mankind Pharma Result Highlights

Mankind Pharma Synopsis

NSE-Medical-Products

Mankind Pharma is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company’s Total Operating Revenue is Rs. 8127.15 Cr. and Equity Capital is Rs. 40.06 Cr. for the Year ended 31/03/2023. Mankind Pharma Ltd. is a Public Limited Listed company incorporated on 03/07/1991 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is U74899DL1991PLC044843 and registration number is 044843.
Market Cap 70,131
Sales 6,109
Shares in Float 9.61
No of funds 177
Yield
Book Value 9.01
U/D Vol ratio 1.2
LTDebt / Equity
Alpha 0.29
Beta -0.52

Mankind Pharma

Owner NameJun-23May-23
Promoters 76.5%76.5%
Mutual Funds 3.92%1.83%
Insurance Companies 0.55%0.51%
Foreign Portfolio Investors 4.18%2.61%
Financial Institutions/ Banks 0.09%
Individual Investors 1.02%4.15%
Others 13.83%14.31%

Mankind Pharma Management

Name Designation
Mr. Ramesh Juneja Chairman & Wholetime Director
Mr. Rajeev Juneja Vice Chairman & Mng.Director
Ms. Sheetal Arora WholeTime Director & CEO
Mr. Satish Kumar Sharma Whole Time Director
Mr. Vivek Kalra Independent Director
Mr. Tilokchand Punamchand Ostwal Independent Director
Mr. Surendra Lunia Independent Director
Mr. Bharat Anand Independent Director
Mr. Vijaya Sampath Independent Director

Mankind Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Mankind Pharma Corporate Action

Date Purpose Remarks
2023-08-02 Quarterly Results
2023-05-30 Audited Results

Mankind Pharma MF Shareholding

Name Amount(cr)
HDFC Mid-Cap Opportunities Fund Growth 47236
SBI Bluechip Fund Regular Growth 38881
Kotak Emerging Equity Scheme Growth 33091
Axis Long Term Equity Fund Growth 31411
HDFC Top 100 Fund Growth 25423
  • Company Name
  • CMP
  • Chg(%)
  • Company Name
  • CMP
  • Chg(%)

Mankind Pharma FAQs

What is Share Price of Mankind Pharma ?

Mankind Pharma share price is ₹1750 As on 26 September, 2023 | 23:37

What is the Market Cap of Mankind Pharma ?

The Market Cap of Mankind Pharma is ₹70131 Cr As on 26 September, 2023 | 23:37

What is the P/E ratio of Mankind Pharma ?

The P/E ratio of Mankind Pharma is As on 26 September, 2023 | 23:37

What is the PB ratio of Mankind Pharma ?

The PB ratio of Mankind Pharma is 9.2 As on 26 September, 2023 | 23:37

Q2FY23